FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171181570> ?p ?o ?g. }

• W2171181570 endingPage "1469" @default.
• W2171181570 startingPage "1460" @default.
• W2171181570 abstract "To compare the cardiovascular risks associated with second-line oral antidiabetic agents added to initial metformin therapy in a large nationwide observational study.We conducted a nationwide retrospective cohort study using the Taiwan National Health Insurance database. A total of 36 118 users of different add-on oral antidiabetic agents (sulphonylureas, glinides, pioglitazone, α-glucosidase inhibitors and dipeptidyl peptidase-4 inhibitors) after initial metformin therapy were included in the analysis. The reference group was sulphonylureas added to metformin, the most commonly used combination regimen. The main outcomes of interest were hospitalizations for any cardiovascular event including acute myocardial infarction, congestive heart failure and ischaemic stroke. In the main analysis, all patients were followed within their initiation groups until the study end, disregarding any changes in treatment status over time.In intention-to-treat analyses, there was no difference in the risk of any cardiovascular event among the add-on combination treatment groups, but significantly lower risks of acute myocardial infarction were found for the glinides plus metformin treatment group (crude hazard ratio 0.52, adjusted hazard ratio 0.39; 95% CI 0.20-0.75) and for the α-glucosidase inhibitors plus metformin treatment group (crude hazard ratio 0.63, adjusted hazard ratio 0.54; 95% CI 0.31-0.95). No difference in risk of congestive heart failure or ischaemic stroke risk was found among the combination treatment groups. In secondary as-treated analyses, similar but less significant associations were found as compared with the primary intention-to-treat analyses for all treatment groups.There were no differences in overall cardiovascular risks among several add-on second-line oral antidiabetic agents; however, glinide plus metformin and α-glucosidase inhibitors plus metformin combination therapies might be associated with lower risks of acute myocardial infarction." @default.
• W2171181570 created "2016-06-24" @default.
• W2171181570 creator A5023067010 @default.
• W2171181570 creator A5029473963 @default.
• W2171181570 creator A5033802039 @default.
• W2171181570 creator A5051036746 @default.
• W2171181570 creator A5067715980 @default.
• W2171181570 creator A5068733168 @default.
• W2171181570 date "2015-05-28" @default.
• W2171181570 modified "2023-10-18" @default.
• W2171181570 title "Cardiovascular risks associated with second‐line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study" @default.
• W2171181570 cites W1521352086 @default.
• W2171181570 cites W1526927233 @default.
• W2171181570 cites W1604800572 @default.
• W2171181570 cites W1965146429 @default.
• W2171181570 cites W1990724339 @default.
• W2171181570 cites W2020353068 @default.
• W2171181570 cites W2029749250 @default.
• W2171181570 cites W2042518766 @default.
• W2171181570 cites W2046206328 @default.
• W2171181570 cites W2050856495 @default.
• W2171181570 cites W2062359643 @default.
• W2171181570 cites W2064130493 @default.
• W2171181570 cites W2078482750 @default.
• W2171181570 cites W2083342497 @default.
• W2171181570 cites W2083557491 @default.
• W2171181570 cites W2087366614 @default.
• W2171181570 cites W2091815896 @default.
• W2171181570 cites W2110265466 @default.
• W2171181570 cites W2112662877 @default.
• W2171181570 cites W2114349038 @default.
• W2171181570 cites W2117465409 @default.
• W2171181570 cites W2123424236 @default.
• W2171181570 cites W2127854619 @default.
• W2171181570 cites W2134455173 @default.
• W2171181570 cites W2142271188 @default.
• W2171181570 cites W2147663252 @default.
• W2171181570 cites W2147764623 @default.
• W2171181570 cites W2150180487 @default.
• W2171181570 cites W2159969745 @default.
• W2171181570 cites W2163980786 @default.
• W2171181570 cites W2171294019 @default.
• W2171181570 cites W2188846692 @default.
• W2171181570 cites W4229984599 @default.
• W2171181570 doi "https://doi.org/10.1111/dme.12800" @default.
• W2171181570 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25970814" @default.
• W2171181570 hasPublicationYear "2015" @default.
• W2171181570 type Work @default.
• W2171181570 sameAs 2171181570 @default.
• W2171181570 citedByCount "29" @default.
• W2171181570 countsByYear W21711815702016 @default.
• W2171181570 countsByYear W21711815702017 @default.
• W2171181570 countsByYear W21711815702018 @default.
• W2171181570 countsByYear W21711815702019 @default.
• W2171181570 countsByYear W21711815702020 @default.
• W2171181570 countsByYear W21711815702021 @default.
• W2171181570 countsByYear W21711815702022 @default.
• W2171181570 countsByYear W21711815702023 @default.
• W2171181570 crossrefType "journal-article" @default.
• W2171181570 hasAuthorship W2171181570A5023067010 @default.
• W2171181570 hasAuthorship W2171181570A5029473963 @default.
• W2171181570 hasAuthorship W2171181570A5033802039 @default.
• W2171181570 hasAuthorship W2171181570A5051036746 @default.
• W2171181570 hasAuthorship W2171181570A5067715980 @default.
• W2171181570 hasAuthorship W2171181570A5068733168 @default.
• W2171181570 hasConcept C126322002 @default.
• W2171181570 hasConcept C127413603 @default.
• W2171181570 hasConcept C134018914 @default.
• W2171181570 hasConcept C167135981 @default.
• W2171181570 hasConcept C201903717 @default.
• W2171181570 hasConcept C207103383 @default.
• W2171181570 hasConcept C2777180221 @default.
• W2171181570 hasConcept C2778198053 @default.
• W2171181570 hasConcept C2778384471 @default.
• W2171181570 hasConcept C2779306644 @default.
• W2171181570 hasConcept C2779668873 @default.
• W2171181570 hasConcept C2780323712 @default.
• W2171181570 hasConcept C2780645631 @default.
• W2171181570 hasConcept C44249647 @default.
• W2171181570 hasConcept C500558357 @default.
• W2171181570 hasConcept C50382708 @default.
• W2171181570 hasConcept C555293320 @default.
• W2171181570 hasConcept C71924100 @default.
• W2171181570 hasConcept C72563966 @default.
• W2171181570 hasConcept C78519656 @default.
• W2171181570 hasConceptScore W2171181570C126322002 @default.
• W2171181570 hasConceptScore W2171181570C127413603 @default.
• W2171181570 hasConceptScore W2171181570C134018914 @default.
• W2171181570 hasConceptScore W2171181570C167135981 @default.
• W2171181570 hasConceptScore W2171181570C201903717 @default.
• W2171181570 hasConceptScore W2171181570C207103383 @default.
• W2171181570 hasConceptScore W2171181570C2777180221 @default.
• W2171181570 hasConceptScore W2171181570C2778198053 @default.
• W2171181570 hasConceptScore W2171181570C2778384471 @default.
• W2171181570 hasConceptScore W2171181570C2779306644 @default.
• W2171181570 hasConceptScore W2171181570C2779668873 @default.
• W2171181570 hasConceptScore W2171181570C2780323712 @default.
• W2171181570 hasConceptScore W2171181570C2780645631 @default.

• next